liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Intralymphatic Immunotherapy: Update and Unmet Needs.
Clinical Trials Center, University Hospital, Zurich, Switzerland.
Clinical Trials Center, University Hospital, Zurich, Switzerland.
Hospital Médica Sur, Mexico City, Mexico.
Department of Clinical Medicine, Aarhus University, Denmark; Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Denmark.
Show others and affiliations
2019 (English)In: International Archives of Allergy and Immunology, ISSN 1018-2438, E-ISSN 1423-0097, Vol. 178, no 2, p. 141-149Article, review/survey (Refereed) Published
Abstract [en]

Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes - intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1 month apart. While the number of patients included in randomised controlled trials is still limited, the clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations.

Place, publisher, year, edition, pages
S. Karger, 2019. Vol. 178, no 2, p. 141-149
Keywords [en]
Allergen-specific immunotherapy, Allergy, Clinical trials, Intralymphatic immunotherapy
National Category
Respiratory Medicine and Allergy
Identifiers
URN: urn:nbn:se:liu:diva-154633DOI: 10.1159/000493647ISI: 000459512200005PubMedID: 30391954OAI: oai:DiVA.org:liu-154633DiVA, id: diva2:1291275
Note

Funding agencies: EAACI Task Force

Available from: 2019-02-24 Created: 2019-02-24 Last updated: 2019-03-08

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Ahlbeck, Lars

Search in DiVA

By author/editor
Ahlbeck, Lars
By organisation
Division of Neuro and Inflammation ScienceFaculty of Medicine and Health SciencesAllergy Center
In the same journal
International Archives of Allergy and Immunology
Respiratory Medicine and Allergy

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 26 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf